Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Sarcoidosis following alemtuzumab treatment for multiple sclerosis

Willis, Mark D ORCID:, Hope-Gill, Ben, Flood-Page, Patrick, Joseph, Fady, Needham, Ed, Jones, Joanne, Coles, Alasdair and Robertson, Neil P ORCID: 2018. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis 24 (13) , 1779-`782. 10.1177/1352458518790391

[thumbnail of Main document_post review_040618_clean.pdf]
PDF - Accepted Post-Print Version
Download (127kB) | Preview


Despite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 50% of individuals will develop a new autoimmune disease following treatment. To date, these have largely been antibody mediated and organ specific (primarily affecting the thyroid gland). In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report three (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher: SAGE Publications
ISSN: 1352-4585
Date of First Compliant Deposit: 25 October 2018
Date of Acceptance: 11 June 2018
Last Modified: 02 May 2023 16:22

Citation Data

Cited 23 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics